Surmodics, Inc., founded in 1979, is a leader in Biotechnology and Medical Devices, headquartered in the United States. The company stands out with its focus on surface modification technologies for intravascular medical devices, as well as the production of chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays.
Operating under the slogan, "To improve the detection and treatment of disease.", Surmodics is dedicated to addressing unmet clinical needs with highly differentiated medical devices. This commitment positions Surmodics for sustained growth and innovation within the Health Care and Manufacturing sectors.
The company's financial robustness is underscored by a recent $125.00M post-IPO debt investment, finalized on 17 October 2022. This investment came from MidCap Financial, highlighting investor confidence in Surmodics' strategic direction and future potential.